From mice and MOF: Rodent models, immune modulation, and outcome in the critically ill

Critical Care Medicine

Volumn 34, Issue 3, 2006, Pages 921-923

  Bauer, Michael ^a   Reinhart, Konrad ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Clinic modeling randomized trial; Granulocyte colony stimulating factor; Sequential hit model

Indexed keywords

ANTIINFECTIVE AGENT; COLONY STIMULATING FACTOR; COLONY STIMULATING FACTOR 1; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL INJURY; ANTIMICROBIAL THERAPY; CLINICAL FEATURE; DETERIORATION; DISEASE ASSOCIATION; DISEASE COURSE; EDITORIAL; GRAM NEGATIVE SEPSIS; HEMATOPOIESIS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENCE; IMMUNOMODULATION; INFLAMMATION; INTENSIVE CARE UNIT; MORTALITY; MOUSE; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; RISK FACTOR; SEPSIS;

ANIMALS; DISEASE MODELS, ANIMAL; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HEMORRHAGE; MICE; RODENTIA; SEPSIS;

EID: 33644583893     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000202439.45624.E8     Document Type: Editorial

References (14)

1. Tracey KJ, Fong Y, Hesse DG, et al: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330:662-664
2. Panacek EA, Marshall JC, Albertson TE, et al: Monoclonal Anti-TNF: A Randomized Controlled Sepsis Study Investigators: Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004; 32:2173-2182
3. Grass G, Neugebauer EA: Afelimomab - Another therapeutic option in sepsis therapy? Crit Care Med 2004; 32:2343-2344
4. Deans KJ, Haley M, Natanson C, et al: Novel therapies for sepsis: A review. J Trauma 2005; 58:867-874
5. Bone RC: Immunologic dissonance: A continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS) Ann Intern Med 1996; 125:680-687
6. Ulloa L, Tracey KJ: The "cytokine profile": A code for sepsis. Trends Mol Med 2005; 11: 56-63
7. Volk HD, Reinke P, Docke WD: Clinical aspects: from systemic inflammation to "immunoparalysis." Chem Immunol 2000; 74: 162-177
8. Barreda DR, Hanington PC, Belosevic M: Regulation of myeloid development and function by colony stimulating factors. Dev Comp Immunol 2004; 28:509-554
9. Pettila V, Takkunen O, Varpula T, et al: Safety of granulocyte colony-stimulating factor (filgrastim) in intubated patients in the intensive care unit: Interim analysis of a prospective, placebo-controlled, double-blind study. Crit Care Med 2000; 28:3620-3625
10. Schneider C, von Aulock S, Zedler S, et al: Perioperative recombinant human granulocyte colony-stimulating factor (Filgrastim) treatment prevents immunoinflammatory dysfunction associated with major surgery. Ann Surg 2004; 239:75-81
11. Schaefer H, Engert A, Grass G, et al: Perioperative granulocyte colony-stimulating factor does not prevent severe infections in patients undergoing esophagectomy for esophageal cancer: A randomized placebo-controlled clinical trial. Ann Surg 2004; 240: 68-75
12. Bauhofer A, Lorenz W, Kohlert F, et al: Granulocyte colony-stimulating factor prophylaxis improves survival and inflammation in a two-hit model of hemorrhage and sepsis. Crit Care Med 2006; 34:778-784
13. Karzai W, von Specht BU, Parent C, et al: G-CSF during Escherichia coli versus Staphylococcus aureus pneumonia in rats has fundamentally different and opposite effects. Am J Respir Crit Care Med 1999; 159: 1377-1382
14. Eskandari MK, Bolgos G, Miller C, et al: Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol 1992; 148:2724-2730